| Primary |
| Anaemia |
24.5% |
| Renal Failure Chronic |
19.2% |
| Product Used For Unknown Indication |
18.3% |
| Anaemia Of Malignant Disease |
10.5% |
| Myelodysplastic Syndrome |
5.4% |
| Hepatitis C |
5.0% |
| Drug Use For Unknown Indication |
4.9% |
| Pre-existing Disease |
2.7% |
| Hypertension |
1.6% |
| Dialysis |
1.3% |
| Nephrogenic Anaemia |
1.2% |
| Diabetes Mellitus |
1.1% |
| Preoperative Care |
1.0% |
| Hiv Infection |
1.0% |
| Breast Cancer Metastatic |
0.6% |
| Blood Pressure |
0.5% |
| Haemoglobin Decreased |
0.5% |
| Pain |
0.4% |
| Renal Disorder |
0.3% |
| Renal Failure |
0.3% |
|
| Death |
32.6% |
| Therapeutic Response Decreased |
11.5% |
| Haemoglobin Decreased |
7.4% |
| Aplasia Pure Red Cell |
5.8% |
| Injection Site Pain |
5.0% |
| Drug Ineffective |
4.7% |
| Hospitalisation |
4.3% |
| Weight Decreased |
3.4% |
| Rash |
3.1% |
| Malaise |
2.4% |
| Vomiting |
2.3% |
| Fatigue |
2.3% |
| Pain In Extremity |
2.2% |
| Oedema Peripheral |
2.2% |
| White Blood Cell Count Decreased |
2.1% |
| Nausea |
2.0% |
| Thrombosis |
1.8% |
| Headache |
1.7% |
| Pulmonary Embolism |
1.7% |
| Pyrexia |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
16.1% |
| Hepatitis C |
15.8% |
| Anaemia |
15.1% |
| Renal Failure Chronic |
9.1% |
| Drug Use For Unknown Indication |
7.0% |
| Hypertension |
6.2% |
| Nephrogenic Anaemia |
6.1% |
| Myelodysplastic Syndrome |
4.9% |
| Anaemia Of Malignant Disease |
4.7% |
| Diabetes Mellitus |
2.7% |
| Anaemia Of Chronic Disease |
2.3% |
| Dialysis |
1.7% |
| Breast Cancer Metastatic |
1.5% |
| Chemotherapy |
1.1% |
| Transplant |
1.1% |
| Renal Transplant |
1.1% |
| Cardiovascular Disorder |
0.9% |
| Immunosuppression |
0.9% |
| Breast Cancer |
0.8% |
| Renal Failure |
0.8% |
|
| Death |
16.8% |
| Therapeutic Response Decreased |
16.5% |
| Aplasia Pure Red Cell |
14.5% |
| Asthenia |
5.6% |
| Nausea |
5.6% |
| Weight Decreased |
4.5% |
| White Blood Cell Count Decreased |
4.0% |
| Haemoglobin Decreased |
3.7% |
| Drug Ineffective |
3.5% |
| Thrombocytopenia |
3.5% |
| Pancytopenia |
3.2% |
| Hospitalisation |
3.1% |
| Reticulocyte Count Decreased |
2.7% |
| Transient Ischaemic Attack |
2.1% |
| Transfusion |
1.9% |
| Anaemia |
1.8% |
| Platelet Count Decreased |
1.8% |
| Syncope |
1.8% |
| Dysplasia |
1.6% |
| Fatigue |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.5% |
| Drug Use For Unknown Indication |
24.6% |
| Multiple Myeloma |
9.1% |
| Hepatitis C |
5.3% |
| Pain |
4.0% |
| Anaemia |
3.9% |
| Nuclear Magnetic Resonance Imaging |
3.9% |
| Hypertension |
3.3% |
| Angiogram |
2.4% |
| Myelodysplastic Syndrome |
2.3% |
| Hiv Infection |
2.3% |
| Prophylaxis |
1.6% |
| Nausea |
1.6% |
| Diabetes Mellitus |
1.5% |
| Depression |
1.4% |
| Nuclear Magnetic Resonance Imaging Brain |
1.2% |
| Breast Cancer |
1.1% |
| Supplementation Therapy |
1.1% |
| Prophylaxis Against Transplant Rejection |
1.0% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
|
| Vomiting |
13.0% |
| White Blood Cell Count Decreased |
10.4% |
| Weight Decreased |
10.2% |
| Thrombocytopenia |
7.8% |
| Death |
7.0% |
| Renal Failure Acute |
5.4% |
| Urinary Tract Infection |
4.7% |
| Weight Increased |
4.4% |
| Anaemia |
3.7% |
| Rash |
3.5% |
| Nausea |
3.3% |
| Platelet Count Decreased |
3.3% |
| Pneumonia |
3.3% |
| Skin Tightness |
3.3% |
| Sepsis |
3.2% |
| Renal Failure |
2.8% |
| Fatigue |
2.8% |
| Pyrexia |
2.7% |
| Thrombophlebitis |
2.7% |
| Syncope |
2.6% |
|
| Interacting |
| Blood Testosterone Increased |
50.0% |
| Prostate Cancer Metastatic |
50.0% |
|
| Poor Peripheral Circulation |
100.0% |
|
